Contact Us   |   Sign In   |   Join CAHR
Market Access 201 - 2018
Share |

MARKET ACCESS 201

Flying Blind – Navigating Patient Access through Uncertainty

Tuesday, June 19, 2018
| Mississauga, On |

 
Join us for Market Access 201 as we explore the evolving reimbursement landscape in Canada, and discuss how patient access may be impacted by an increasingly uncertain reimbursement environment.

WHO SHOULD ATTEND? Anyone who wants to learn more about market access should consider joining us, and if you are seeking your Market Access Certification through our CMAP program this is a must-attend event!


COST - Includes conference materials, breakfast, lunch and two breaks.

 

CAHR Member: $850.00   Non-Member: $995.00   Student: $75.00

13% HST applicable on all fees

 



 

AGENDA


EMCEE FOR THE DAY:
Jeffrey Hoch, PhD, Professor, Department of Public Health Sciences, Associate Director, Center for Healthcare Policy and Research UC Davis


PANEL ONE

Patented Medicine Prices Review Board (PMPRB)
This panel will explore questions about how the PMPRB consultations will unfold, how the remaining details will be developed, what transition measures will look like and what impact the final guidelines will have on current prices and new drug prices.

MODERATOR: Joan McCormick, Principal, IQVIA

PANELISTS:
  Matt Kellison,
PMPRB, Director, Regulatory Affairs and Outreach
  Lauren Fischer,
Vice President of Corporate Affairs, Eli Lilly Canada
  Legal Perspective - Panelist to be confirmed



PANEL TWO

Pan-Canadian Pharmaceutical Alliance (pCPA)

This panel will focus on recent events surrounding the pCPA and how public payers believe that PMPRB reform may impact upcoming pCPA negotiations.

MODERATOR: Sherry O’Quinn, Managing Principal, MORSE


PANELISTS:
  Imran Ali,
Senior Manager, pan-Canadian Pharmaceutical Alliance (pCPAO)
  Public Payer
- Panelist to be confirmed
  Industry Representative
- Panelist to be confirmed



PANEL THREE

Health Technology Assessment (HTA)

This panel will explore current developments and the evolving role of health technology assessment (HTA) for both oncology and non-oncology drugs. It will focus on HTA processes and contrasts and compares how CDR, pCODR, and INESSS evaluates new treatments.

MODERATOR: Angela Rocchi,
Principal, Athena Research

PANELISTS:
  CDR Representative
- Panelist to be confirmed
  pCODR Representative
- Panelist to be confirmed
  INESSS Representative
- Panelist to be confirmed


PANEL FOUR

Pharmacoeconomics (PE)
This panel will focus on the growing influence of pharmacoeconomics in the Canadian reimbursement process. It will discuss the implications of the revised CADTH PE guidelines on CDR and pCODR reviews. The panelists will also discuss the implications of using PE thresholds for price regulations. In addition, the impact of PE models on pCPA negotiations will also be explored in this session.

MODERATOR: Chris Cameron,
Senior Director, Cornerstone Research Group

PANELISTS:
  Professor Doug Coyle
(Interim Director and Professor) School of Epidemiology and Public Health
  Don Husereau,
Senior Associate, Institute for Health Economics
  Brad Alyward,
Principal Consultant, MORSE Consulting Inc.
  Matt Kellison,
PMPRB, Director, Regulatory Affairs and Outreach


PANEL FIVE

Patient Support Programs (PSPs)
This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel.

MODERATOR: Allison Wills,
Partner, 20Sense Specialty Pharmaceutical Consulting

PANELISTS:
   Sang Mi Lee,
Senior Pharmacist, pCPA Office
   Greg Rutherford, Director Pharmaceutical Solutions, McKesson
   Janey Shin, Director, RWE, Janssen



PANEL SIX

Presidents’ Roundtable
This session will bring together general managers from three innovative pharmaceutical companies operating in Canada to explore their insights on how the current reimbursement environment is impacting their company, its decision-making and patient access.


MODERATOR: Jeffrey Hoch,
PhD, Professor, Department of Public Health Sciences, Associate Director, Center for Healthcare Policy and Research UC Davis

PANELISTS:
   Peter Brenders,
General Manager, Sanofi Genzyme Canada
   Brian Canestraro,
Intercept Pharmaceuticals
   Ben Faienza,
Country Representative, UCB Canada

CAHR reserves the right to cancel or change speakers, program content and date without prior notice.
We assume no liability for these changes
.

For more information please contact the CAHR office. 416.494.1440 x221 or email at office@cahr-acrss.ca



 

Click Here to Register Today!

 


CAHR Member: $850.00 Non-Member: $995.00 Student: $75.00 (13% HST is applicable)

 

Thank you to our partners!

 

    
     
 
             
 



Membership Software Powered by YourMembership  ::  Legal